Amy Chappell, M. SLX-100, a novel immediate release formulation of 4-aminopyridine, for the treatment of Spinocerebellar Ataxia 27B (SCA27B), an orphan disease. Elsevier.
Chicago Style (17th ed.) CitationAmy Chappell, M.D. SLX-100, a Novel Immediate Release Formulation of 4-aminopyridine, for the Treatment of Spinocerebellar Ataxia 27B (SCA27B), an Orphan Disease. Elsevier.
MLA (9th ed.) CitationAmy Chappell, M.D. SLX-100, a Novel Immediate Release Formulation of 4-aminopyridine, for the Treatment of Spinocerebellar Ataxia 27B (SCA27B), an Orphan Disease. Elsevier.
Warning: These citations may not always be 100% accurate.